Jacobs Levy Equity Management
LPCN icon

Jacobs Levy Equity Management’s Lipocine LPCN Stock Holding History

Jacobs Levy Equity Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,532
Closed -$83K – 1032
2018
Q3 		$83K Sell
3,532
-286
-7% -$7.03K ﹤0.01% 967
2018
Q2 		$84K Buy
+3,818
New +$91K ﹤0.01% 998
2017
Q1 		– Sell
-782
Closed -$49K – 964
2016
Q4 		$49K Buy
+782
New +$49.5K ﹤0.01% 937

Other funds holding LPCN

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management's LPCN Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Lipocine (LPCN) in Q4 2018, closing a stake of 3,532 shares — an estimated $83K sold.

Jacobs Levy Equity Management first reported a position in LPCN in Q4 2016 and held it in 3 quarters. The position peaked at $84K in Q2 2018. 24 funds tracked by Wall St. Rank hold LPCN as of Q4 2018.

  • Jacobs Levy Equity Management reported no remaining Lipocine position as of Q4 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,532 Lipocine shares in Q4 2018, an estimated $83K.
  • Jacobs Levy Equity Management first reported a position in Lipocine in Q4 2016 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Lipocine position peaked at $84K in Q2 2018.
  • 24 funds tracked by Wall St. Rank held Lipocine as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.